On July 28, 2021 Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics, reported that it has signed a global collaboration and license agreement with Jiangsu Nhwa Pharmaceutical Co., one of China’s leading CNS companies, to develop Cell Penetrating Alphabodies (CPABs) able to cross the blood brain barrier, for the improved treatment of diseases of the central nervous system (CNS) (Press release, Complix, JUL 28, 2021, View Source;utm_medium=rss&utm_campaign=complix-signs-global-drug-discovery-and-development-agreement-with-jiangsu-nhwa-pharmaceutical-co-to-develop-novel-alphabody-therapeutics-for-treatment-of-cns-diseases [SID1234585443]). This agreement is an important corporate milestone for Complix, as it seeks to apply its industry leading CPAB platform in yet another major disease area, beyond oncology, autoimmunity, and viral diseases.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Jiangsu Nhwa Pharmaceutical Co. (Nhwa) is a leading CNS company in China, which has developed an innovative and differentiated pipeline in the areas of anesthesia, analgesia, psychiatry, and neurology via both its own in-house R&D and global partnerships. Nhwa has more than 4000 employees, with capabilities in research, clinical development, manufacturing, and commercialization of CNS drugs.
Complix and Nhwa will collaborate to develop novel biotherapeutics against two selected CNS targets. Complix will apply its proprietary CPAB technology, that enables biologics to traverse membrane systems and act with high affinity and precision on disease targets that are considered intractable by current drug formats. The novel compounds to be developed under this collaboration, will be designed to cross the blood brain barrier to address important disease targets in the central nervous system.
Under the terms of the agreement, Complix has granted an exclusive license to Nhwa to develop, manufacture and commercialize the CPABs resulting from this collaboration in Greater China. Both companies retain joint development and commercialization rights for these CPABs in the rest of the world.
Complix is entitled to upfront license payments and further milestone payments subject to the progress of clinical development and regulatory approval. Complix is also eligible for royalty payments based on the future commercial sales of the CPABs in China.
Mark Vaeck, CEO of Complix, said:
"We are thrilled to announce this exciting collaboration with Nhwa. We are confident that the unique targeting capabilities of our CPABs will allow us to jointly develop novel biotherapeutics that will deliver improved treatment outcomes for patients suffering from severe neurological diseases. We believe that partnering with an innovative company like Nhwa, specialized in the area of CNS diseases, is substantially value creating, as it provides access to significant research and clinical development expertise in the CNS area, as well as a strong commercial platform in China. I am confident that together we can deliver on our ambitions to develop innovative and highly needed solutions for patients with severe neurological conditions".
Jiaquan Sun, CEO of Jiangsu Nhwa added:
"We are pleased to collaborate with Complix to gain access to its highly innovative CPAB platform as we look to further strengthen our position as a market leader in CNS therapies in China. We are looking forward to working with the team at Complix as we tap into their world leading intracellular targeting expertise to generate novel therapeutics that can cross the blood brain barrier to address major unmet medical needs that still exist in the CNS disease area today’’.